Jiangsu Lianhuan Pharmaceutical Co Ltd - Asset Resilience Ratio
Jiangsu Lianhuan Pharmaceutical Co Ltd (600513) has an Asset Resilience Ratio of 0.00% as of September 2021. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2020)
This chart shows how Jiangsu Lianhuan Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. Check 600513 capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Jiangsu Lianhuan Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Jiangsu Lianhuan Pharmaceutical Co Ltd market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥81.18K | 0.0% |
| Total Liquid Assets | CN¥81.18K | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Jiangsu Lianhuan Pharmaceutical Co Ltd maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Jiangsu Lianhuan Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Jiangsu Lianhuan Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Alkem Laboratories Limited
NSE:ALKEM |
Drug Manufacturers - Specialty & Generic | 31.91% |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423 |
Drug Manufacturers - Specialty & Generic | 20.44% |
|
Alkermes plc
F:8AK |
Drug Manufacturers - Specialty & Generic | 3.76% |
|
Jilin Aodong Pharmaceutical Group Co Ltd
SHE:000623 |
Drug Manufacturers - Specialty & Generic | 4.97% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131 |
Drug Manufacturers - Specialty & Generic | 1.37% |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436 |
Drug Manufacturers - Specialty & Generic | -2.56% |
Annual Asset Resilience Ratio for Jiangsu Lianhuan Pharmaceutical Co Ltd (2000–2020)
The table below shows the annual Asset Resilience Ratio data for Jiangsu Lianhuan Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2020-12-31 | 0.00% | CN¥38.43K ≈ $5.62K |
CN¥2.05 Billion ≈ $299.84 Million |
0.00pp |
| 2019-12-31 | 0.00% | CN¥45.18K ≈ $6.61K |
CN¥1.89 Billion ≈ $276.51 Million |
0.00pp |
| 2018-12-31 | 0.00% | CN¥41.85K ≈ $6.12K |
CN¥1.42 Billion ≈ $207.80 Million |
0.00pp |
| 2017-12-31 | 0.00% | CN¥51.48K ≈ $7.53K |
CN¥1.16 Billion ≈ $170.40 Million |
0.00pp |
| 2016-12-31 | 0.00% | CN¥52.29K ≈ $7.65K |
CN¥1.07 Billion ≈ $156.03 Million |
0.00pp |
| 2015-12-31 | 0.01% | CN¥54.45K ≈ $7.97K |
CN¥1.00 Billion ≈ $146.41 Million |
-0.04pp |
| 2014-12-31 | 0.05% | CN¥305.78K ≈ $44.75K |
CN¥658.96 Million ≈ $96.43 Million |
+0.02pp |
| 2013-12-31 | 0.03% | CN¥179.80K ≈ $26.31K |
CN¥649.48 Million ≈ $95.04 Million |
-0.02pp |
| 2012-12-31 | 0.05% | CN¥218.82K ≈ $32.02K |
CN¥443.21 Million ≈ $64.86 Million |
0.00pp |
| 2011-12-31 | 0.05% | CN¥218.27K ≈ $31.94K |
CN¥418.52 Million ≈ $61.24 Million |
-0.01pp |
| 2010-12-31 | 0.06% | CN¥234.78K ≈ $34.36K |
CN¥401.08 Million ≈ $58.69 Million |
-0.07pp |
| 2009-12-31 | 0.13% | CN¥510.75K ≈ $74.74K |
CN¥383.36 Million ≈ $56.10 Million |
+0.08pp |
| 2008-12-31 | 0.06% | CN¥208.76K ≈ $30.55K |
CN¥359.66 Million ≈ $52.63 Million |
+0.00pp |
| 2007-12-31 | 0.06% | CN¥206.85K ≈ $30.27K |
CN¥357.66 Million ≈ $52.34 Million |
+0.03pp |
| 2006-12-31 | 0.03% | CN¥94.40K ≈ $13.81K |
CN¥335.84 Million ≈ $49.14 Million |
-0.10pp |
| 2004-12-31 | 0.13% | CN¥400.00K ≈ $58.53K |
CN¥312.05 Million ≈ $45.66 Million |
-0.01pp |
| 2003-12-31 | 0.14% | CN¥400.00K ≈ $58.53K |
CN¥293.21 Million ≈ $42.91 Million |
+0.10pp |
| 2000-12-31 | 0.03% | CN¥35.33K ≈ $5.17K |
CN¥103.67 Million ≈ $15.17 Million |
-- |
About Jiangsu Lianhuan Pharmaceutical Co Ltd
Jiangsu Lianhuan Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells pharmaceuticals, preparations, and active pharmaceutical ingredients (API) products in China and internationally. The company offers clopidogrel bisulfate tablets, doxycycline hydrochloride, azithromycin, milrinone, dapoxetine hydrochloride, tadalafil, and betasine besylate tablets, as well as aprili… Read more